Prospects for Moxidectin as a New Oral Treatment for Human Scabies

PLoS Neglected Tropical Diseases

Volumn 10, Issue 3, 2016, Pages

  Mounsey, Kate E ^a,b   Bernigaud, Charlotte ^c   Chosidow, Olivier ^c,d   McCarthy, James S ^b,e  

^a UNIVERSITY OF THE SUNSHINE COAST   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c HENRI MONDOR HOSPITAL   (France)

^d UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^e UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

IVERMECTIN; MOXIDECTIN; ACARICIDE; MACROLIDE; MILBEMYCIN;

ALGORITHM; ARTICLE; COMMUNITY CARE; DRUG MEGADOSE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; HUMAN; NONHUMAN; ONCHOCERCIASIS; PHARMACODYNAMICS; PREVALENCE; SCABIES; SINGLE DRUG DOSE; VACCINATION; WORLD HEALTH ORGANIZATION; ANIMAL; CLINICAL TRIAL (TOPIC); DISEASE MODEL; DRUG REPOSITIONING; ORAL DRUG ADMINISTRATION; PRECLINICAL STUDY;

ACARICIDES; ADMINISTRATION, ORAL; ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; DRUG REPOSITIONING; HUMANS; MACROLIDES; SCABIES;

EID: 84962359349     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0004389     Document Type: Article

References (52)

1. World Health Organization. Scabies. http://www.who.int/lymphatic_filariasis/epidemiology/scabies/en/. Accessed 27/2/2016.
2. Engelman D, Kiang K, Chosidow O, McCarthy J, Fuller C, et al. (2013) Toward the global control of human scabies: introducing the International Alliance for the Control of Scabies. PLoS Negl Trop Dis7: e2167. doi: 10.1371/journal.pntd.000216723951369
3. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, et al. (2012) Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet380: 2197–2223. doi: 10.1016/S0140-6736(12)61689-423245608
4. Romani L, Steer AC, Whitfeld MJ, Kaldor JM, (2015) Prevalence of scabies and impetigo worldwide: a systematic review. Lancet Infect Dis15: 960–967. doi: 10.1016/S1473-3099(15)00132-226088526
5. Hotez PJ, Alvarado M, Basanez MG, Bolliger I, Bourne R, et al. (2014) The global burden of disease study 2010: interpretation and implications for the neglected tropical diseases. PLoS Negl Trop Dis8: e2865. doi: 10.1371/journal.pntd.000286525058013
6. Mounsey KE, Murray HC, Bielefeldt-Ohmann H, Pasay C, Holt DC, et al. (2015) Prospective study in a porcine model of Sarcoptes scabiei indicates the association of Th2 and Th17 pathways with the clinical severity of scabies. PLoS Negl Trop Dis9: e0003498. doi: 10.1371/journal.pntd.000349825730203
7. Liu X, Walton S, Mounsey K, (2014) Vaccine against scabies: necessity and possibility. Parasitology141: 725–732. doi: 10.1017/S003118201300204724476932
8. Reynolds SL, Pike RN, Mika A, Blom AM, Hofmann A, et al. (2014) Scabies mite inactive serine proteases are potent inhibitors of the human complement lectin pathway. PLoS Negl Trop Dis8: e2872. doi: 10.1371/journal.pntd.000287224854034
9. Chosidow O, (2006) Clinical practices. Scabies. N Engl J Med354: 1718–1727. 16625010
10. Strong M, Johnstone PW, (2010) Interventions for treating scabies (update). Cochrane Database Syst Rev: CD000320.
11. Pasay C, Arlian L, Morgan M, Gunning R, Rossiter L, et al. (2009) The effect of insecticide synergists on the response of scabies mites to pyrethroid acaricides. PLoS Negl Trop Dis3: e354. doi: 10.1371/journal.pntd.000035419125173
12. Andrews R, Kearns T, Connors C, Parker C, Carville K, et al. (2009) A Regional Initiative to Reduce Skin Infections amongst Aboriginal Children Living in Remote Communities of the Northern Territory, Australia. PLoS Negl Trop Dis3: e554. doi: 10.1371/journal.pntd.000055419936297
13. La Vincente S, Kearns T, Connors C, Cameron S, Carapetis J, et al. (2009) Community management of endemic scabies in remote aboriginal communities of northern Australia: low treatment uptake and high ongoing acquisition. PLoS Negl Trop Dis3: e444. doi: 10.1371/journal.pntd.000044419478832
14. Hewitt KA, Nalabanda A, Cassell JA, (2015) Scabies outbreaks in residential care homes: factors associated with late recognition, burden and impact. A mixed methods study in England. Epidemiol Infect143: 1542–1551. doi: 10.1017/S095026881400214325195595
15. Lawrence G, Sheridan J, Speare R, (1994) We can get rid of scabies: new treatment available soon. Med J Aust161: 232.
16. Therapeutic Goods Administration, Australian Govermernment Deartment of Health. Australian Public Assessment Report: Ivermectin. http://tga.gov.au/auspar/auspar-ivermectin. Accessed 22/9/2015
17. Haar K, Romani L, Filimone R, Kishore K, Tuicakau M, et al. (2014) Scabies community prevalence and mass drug administration in two Fijian villages. Int J Dermatol53: 739–745. doi: 10.1111/ijd.1235324168177
18. Lawrence G, Leafasia J, Sheridan J, Hills S, Wate J, et al. (2005) Control of scabies, skin sores and haematuria in children in the Solomon Islands: another role for ivermectin. Bull World Health Org83: 34–42. 15682247
19. Kearns TM, Speare R, Cheng AC, McCarthy J, Carapetis JR, et al. (2015) Impact of an Ivermectin Mass Drug Administration on Scabies Prevalence in a Remote Australian Aboriginal Community.PLoS Negl Trop Dis9: e0004151. doi: 10.1371/journal.pntd.000415126516764
20. Gyapong JO, Chinbuah MA, Gyapong M, (2003) Inadvertent exposure of pregnant women to ivermectin and albendazole during mass drug administration for lymphatic filariasis. Trop Med Int Health8: 1093–1101. 14641844
21. Ndyomugyenyi R, Kabatereine N, Olsen A, Magnussen P, (2008) Efficacy of ivermectin and albendazole alone and in combination for treatment of soil-transmitted helminths in pregnancy and adverse events: a randomized open label controlled intervention trial in Masindi district, western Uganda. Am J Trop Med Hyg79: 856–863. 19052293
22. Clucas D, Carville K, Connors C, Currie B, Carapetis J, et al. (2008) Disease burden and health-care clinic attendances for young children in remote Aboriginal communities of northern Australia. Bull World Health Org86: 241–320.
23. Pariser DM, Meinking TL, Bell M, Ryan WG, (2012) Topical 0.5% ivermectin lotion for treatment of head lice. N Engl J Med367: 1687–1693. doi: 10.1056/NEJMoa120010723113480
24. Chosidow O, Giraudeau B, Cottrell J, Izri A, Hofmann R, et al. (2010) Oral ivermectin versus malathion lotion for difficult-to-treat head lice. N Engl J Med362: 896–905. doi: 10.1056/NEJMoa090547120220184
25. Stein L, Kircik L, Fowler J, Tan J, Draelos Z, et al. (2014) Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. J Drugs Dermatol13: 316–323. 24595578
26. Taieb A, Ortonne J, Ruzicka T, Roszkiewicz J, Berth-Jones J, et al. (2015) Superiority of ivermectin 1% cream over metronidazole 0·75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial. Br J Dermatol172: 1103–1110. doi: 10.1111/bjd.1340825228137
27. Food and Drug Administration, U.S Department of Health and Human Serices. Prescribing information, Soolantra. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206255lbl.pdf. Accessed 1/12/15.
28. Currie BJ, Harumal P, McKinnon M, Walton SF, (2004) First documentation of in vivo and in vitro ivermectin resistance in Sarcoptes scabiei. Clin Infect Dis39: e8–12. 15206075
29. Mounsey K, Holt D, McCarthy J, Currie B, Walton S, (2009) Longitudinal evidence of increasing in vitro tolerance of scabies mites to ivermectin in scabies-endemic communities. Arch Derm145: 840–841. doi: 10.1001/archdermatol.2009.12519620572
30. Currie B, McCarthy J, (2010) Permethrin and Ivermectin for Scabies. N Engl J Med362: 717–725. doi: 10.1056/NEJMct091032920181973
31. Chosidow O, Giraudeau B, (2012) Topical ivermectin: a step toward making head lice dead lice?N Engl J Med367: 1750–1752. doi: 10.1056/NEJMe121112423113487
32. Haas N, Lindemann U, Frank K, Sterry W, Lademann J, et al. (2002) Rapid and preferential sebum secretion of ivermectin: A new factor that may determine drug responsiveness in patients with scabies. Arch Derm138: 1618–1619. 12472363
33. Fujimoto K, Kawasaki Y, Morimoto K, Kikuchi I, Kawana S, (2014) Treatment for crusted scabies: Limitations and side effects of treatment with Ivermectin. J Nippon Med Sch81: 157–163. 24998962
34. Chouela EN, Abeldano AM, Pellerano G, La Forgia M, Papale RM, et al. (1999) Equivalent therapeutic efficacy and safety of ivermectin and lindane in the treatment of human scabies. Arch Derm135: 651–655. 10376691
35. Glaziou P, Cartel JL, Alzieu P, Briot C, Moulia-Pelat JP, et al. (1993) Comparison of ivermectin and benzyl benzoate for treatment of scabies. Trop Med Parasitol44: 331–332. 8134777
36. Ly F, Caumes E, Ndaw CAT, Ndiaye B, Mahe A, (2009) Ivermectin versus benzyl benzoate applied once or twice to treat human scabies in Dakar, Senegal: a randomized controlled trial. Bull World Health Org87: 424–430. 19565120
37. Prichard R, Menez C, Lespine A, (2012) Moxidectin and the avermectins: Consanguinity but not identity. Int J Parasitol: Drugs Drug Resist2: 134–153.
38. Losson B, Lonneux JF, (1993) Field efficacy of injectible moxidectin in cattle naturally infested with Chorioptes bovis and Sarcoptes scabiei. Vet Parasitol51: 113–121. 8128574
39. Fthenakis GC, Papadopolous E, Himonas C, Leontides L, Kritas S, et al. (2000) Efficacy of moxidectin against sarcoptic mange and effects on milk yiled of ewes and growth of lambs. Vet Parasitol87: 207–216. 10622612
40. Hidalgo Arguello MR, Diez-Banos N, Martinez-Gonzalez B, Rojo-Vazquez FA, (2001) Efficacy of moxidectin 1% injectable against natural infection of Sarcoptes scabiei in sheep. Vet Parasitol102: 143–150. 11705660
41. Astiz S, Legaz-Huidobro E, Mottier L, (2011) Efficacy of long-acting moxidectin against sarcoptic mange in naturally infested sheep. Vet Rec169: 637a.
42. Papadopolous E, Fthenakis GC, Himonas C, Tzora A, Leontides L, (2000) Persistent efficacy of moxidectin against Sarcoptes scabiei in sheep. J Vet Pharmacol Ther23: 111–112. 10849257
43. Butters MP, Kobylinski KC, Deus KM, da Silva IM, Gray M, et al. (2012) Comparative evaluation of systemic drugs for their effects against Anopheles gambiae. Acta Trop121: 34–43. doi: 10.1016/j.actatropica.2011.10.00722019935
44. Bernigaud C, Fang F, Fischer K, Lespine A, Kelly A, et al. (2015) Experimental pig model of scabies: comparative activity of oral ivermectin and moxidectin. 25th European Society of Clinical Microbiology and Infectious Diseases. Copenhagen.
45. Cotreau MM, Warren S, Ryan JL, Fleckenstein L, Vanapalli SR, et al. (2003) The antiparasitic moxidectin: safety, tolerability, and pharmacokinetics in humans. J Clin Pharmacol43: 1108–1115. 14517193
46. Korth-Bradley JM, Parks V, Chalon S, Gourley I, Matschke K, et al. (2011) Excretion of moxidectin into breast milk and pharmacokinetics in healthy lactating women. Antimicrob Agents Chemother55: 5200–5204. doi: 10.1128/AAC.00311-1121896908
47. Awadzi K, Opoku NO, Attah SK, Lazdins-Helds J, Kuesel AC, (2014) A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in Onchocerca volvulus infection. PLoS Negl Trop Dis8: e2953. doi: 10.1371/journal.pntd.000295324968000
48. Bourguinat C, Kamgno J, Boussinesq M, Mackenzie CD, Prichard RK, et al. (2010) Analysis of the mdr-1 gene in patients co-infected with Onchocerca volvulus and Loa loa who experienced a post-ivermectin serious adverse event. Am J Trop Med Hyg83: 28–32.
49. Ito T, (2013) Mazzotti reaction with eosinophilia after undergoing oral ivermectin for scabies. J Dermatol40: 776–777. doi: 10.1111/1346-8138.1224323855317
50. Center for Drug Evaluation,U.S Food and Drug Administration. Guidance for Industry: Product Development Under the Animal Rule. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM399217.pdf. Accessed 22/9/2015.
51. Mounsey K, Ho MF, Kelly A, Willis C, Pasay C, et al. (2010) A tractable experimental model for study of human and animal scabies. PLoS Negl Trop Dis4: e756. doi: 10.1371/journal.pntd.000075620668508
52. Craven J, Bjorn H, Hennessy D, Friis C, Nansen P, (2001) Pharmacokinetics of moxidectin and ivermectin following intravenous injection in pigs with different body compositions. J Vet Pharmacol Ther24: 99–104. 11442783